Recent technological updates and clinical applications of induced pluripotent stem cells

키워드

참고문헌 (77)

1. Somorjai IM, "Stem cells: a view from the roots", Biotechnol J, 7, pp.704~722 (2012)
2. Grskovic M, "Induced pluripotent stem cells: opportunities for disease modelling and drug discovery", Nat Rev Drug Discov, 10, pp.915~929 (2011)
3. Schugar RC, "Small molecules in stem cell self-renewal and differentiation", Gene Ther, 15, pp.126~135 (2008)
4. Murry CE, "Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development", Cell, 132, pp.661~680 (2008)
5. Zaehres H, "Induction of pluripotency: from mouse to human", Cell, 131, pp.834~835 (2007)
6. Takahashi K, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", Cell, 126, pp.663~676 (2006)
7. Maherali N, "Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution", Cell Stem Cell, 1, pp.55~70 (2007)
8. Jaenisch R, "Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming", Cell, 132, pp.567~582 (2008)
9. Takahashi K, "Induction of pluripotent stem cells from adult human fibroblasts by defined factors", Cell, 131, pp.861~872 (2007)
10. Yu J, "Induced pluripotent stem cell lines derived from human somatic cells", Science, 318, pp.1917~1920 (2007)
11. Chang CW, "Polycistronic lentiviral vector for “hit and run” reprogramming of adult skin fibroblasts to induced pluripotent stem cells", Stem Cells, 27, pp.1042~1049 (2009)
12. Feng B, "Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells", Cell Stem Cell, 4, pp.301~312 (2009)
13. Heinrich EM, "MicroRNAs and stem cells:control of pluripotency, reprogramming, and lineage commitment", Circ Res, 110, pp.1014~1022 (2012)
14. Kretsovali A, "Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming", Stem Cells Int, 2012, pp.184154~ (2012)
15. Bayart E, "Technological overview of iPS induction from human adult somatic cells", Curr Gene Ther, 13, pp.73~92 (2013)
16. Gonzalez F, "Methods for making induced pluripotent stem cells: reprogramming a la carte", Nat Rev Genet, 12, pp.231~242 (2011)
17. Stadtfeld M, "Induced pluripotent stem cells generated without viral integration", Science, 322, pp.945~949 (2008)
18. Stadtfeld M, "Induced pluripotency:history, mechanisms, and applications", Genes Dev, 24, pp.2239~2263 (2010)
19. Zhou H, "Generation of induced pluripotent stem cells using recombinant proteins", Cell Stem Cell, 4, pp.381~384 (2009)
20. Jia F, "A nonviral minicircle vector for deriving human iPS cells", Nat Methods, 7, pp.197~199 (2010)
21. Warren L, "Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA", Cell Stem Cell, 7, pp.618~630 (2010)
22. Hayden EC, "California ponders cell-banking venture", Nature, 472, pp.403~ (2011)
23. Fusaki N, "Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome", Proc Jpn Acad Ser B Phys Biol Sci, 85, pp.348~362 (2009)
24. Dowey SN, "Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression", Nat Protoc, 7, pp.2013~2021 (2012)
25. Ban H, "Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors", Proc Natl Acad Sci U S A, 108, pp.14234~14239 (2011)
26. Okita K, "Generation of mouse induced pluripotent stem cells without viral vectors", Science, 322, pp.949~953 (2008)
27. Gonzalez F, "Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector", Proc Natl Acad Sci U S A, 106, pp.8918~8922 (2009)
28. Diecke S, "Cardiac Tissue Engineering: Methods and Protocols. Vol. 1181" (2014), Humana Press
29. Yu J, "Human induced pluripotent stem cells free of vector and transgene sequences", Science, 324, pp.797~801 (2009)
30. Lu J, "The extragenic spacer length between the 5’ and 3’ ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors", Mol Ther, 20, pp.2111~2119 (2012)
31. Chen ZY, "Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo", Mol Ther, 8, pp.495~500 (2003)
32. Narsinh KH, "Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors", Nat Protoc, 6, pp.78~88 (2011)
33. Lu J, "A mini-intronic plasmid (MIP):a novel robust transgene expression vector in vivo and in vitro", Mol Ther, 21, pp.954~963 (2013)
34. Hung SC, "Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1", Proc Natl Acad Sci U S A, 98, pp.1865~1870 (2001)
35. Okita K, "An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells", Stem Cells, 31, pp.458~466 (2013)
36. Mandal PK, "Reprogramming human fibroblasts to pluripotency using modified mRNA", Nat Protoc, 8, pp.568~582 (2013)
37. Colamonici OR, "Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling", J Biol Chem, 270, pp.15974~15978 (1995)
38. Amit M, "No evidence for infection of human embryonic stem cells by feeder cell-derived murine leukemia viruses", Stem Cells, 23, pp.761~771 (2005)
39. Warren L, "Feeder-free derivation of human induced pluripotent stem cells with messenger RNA", Sci Rep, 2, pp.657~ (2012)
40. Yoshioka N, "Efficient generation of human iPSCs by a synthetic self-replicative RNA", Cell Stem Cell, 13, pp.246~254 (2013)
41. Kim D, "Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins", Cell Stem Cell, 4, pp.472~476 (2009)
42. Lee J, "Activation of innate immunity is required for efficient nuclear reprogramming", Cell, 151, pp.547~558 (2012)
43. Hou P, "Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds", Science, 341, pp.651~654 (2013)
44. Zwaka TP, "Homologous recombination in human embryonic stem cells", Nat Biotechnol, 21, pp.319~321 (2003)
45. Hockemeyer D, "Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases", Nat Biotechnol, 27, pp.851~857 (2009)
46. Ding Q, "A TALEN genome-editing system for generating human stem cell-based disease models", Cell Stem Cell, 12, pp.238~251 (2013)
47. Horii T, "Genome engineering of mammalian haploid embryonic stem cells using the Cas9", RNA system, 2013, pp.1, e230~
48. Cheng LT, "Genome editing in induced pluripotent stem cells", Genes Cells, 17, pp.431~438 (2012)
49. Kim H, "A guide to genome engineering with programmable nucleases", Nat Rev Genet, 15, pp.321~334 (2014)
50. Robinton DA, "The promise of induced pluripotent stem cells in research and therapy", Nature, 481, pp.295~305 (2012)
51. Tiscornia G, "Diseases in a dish: modeling human genetic disorders using induced pluripotent cells", Nat Med, 17, pp.1570~1576 (2011)
52. Urbach A, "Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells", Stem Cells, 22, pp.635~641 (2004)
53. Park IH, "Disease-specific induced pluripotent stem cells", Cell, 134, pp.877~886 (2008)
54. Dimos JT, "Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons", Science, 321, pp.1218~1221 (2008)
55. Urbach A, "Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells", Cell Stem Cell, 6, pp.407~411 (2010)
56. Carvajal-Vergara X, "Patient-specif ic induced pluripotent stem-cell-derived models of LEOPARD syndrome", Nature, 465, pp.808~812 (2010)
57. Yazawa M, "Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome", Nature, 471, pp.230~234 (2011)
58. Itzhaki I, "Modelling the long QT syndrome with induced pluripotent stem cells", Nature, 471, pp.225~229 (2011)
59. Brennand KJ, "Modelling schizophrenia using human induced pluripotent stem cells", Nature, 473, pp.221~225 (2011)
60. Jang J, "Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients", Ann Neurol, 70, pp.402~409 (2011)
61. Perel P, "Comparison of treatment effects between animal experiments and clinical trials: systematic review", BMJ, 334, pp.197~ (2007)
62. Frey-Vasconcells J, "Translation of stem cell research: points to consider in designing preclinical animal studies", Stem Cells Transl Med, 1, pp.353~358 (2012)
63. Kramer AS, "Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury", Cell Transplant, 22, pp.571~617 (2013)
64. Kola I, "Can the pharmaceutical industry reduce attrition rates?", Nat Rev Drug Discov, 3, pp.711~715 (2004)
65. Irion S, "Directed differentiation of pluripotent stem cells: from developmental biology to therapeutic applications", Cold Spring Harb Symp Quant Biol, 73, pp.101~110 (2008)
66. Zhu H, "Investigating monogenic and complex diseases with pluripotent stem cells", Nat Rev Genet, 12, pp.266~275 (2011)
67. Saha K, "Technical challenges in using human induced pluripotent stem cells to model disease", Cell Stem Cell, 5, pp.584~595 (2009)
68. Miller JD, "Human iPSC-based modeling of late-onset disease via progerin-induced aging", Cell Stem Cell, 13, pp.691~705 (2013)
69. Wernig M, "Neurons derived from reprogrammed f ibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s disease", Proc Natl Acad Sci U S A, 105, pp.5856~5861 (2008)
70. Hanna J, "Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin", Science, 318, pp.1920~1923 (2007)
71. Lui KO, "Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy", Curr Stem Cell Res Ther, 4, pp.70~80 (2009)
72. Takebe T, "Vascularized and functional human liver from an iPSC-derived organ bud transplant", Nature, 499, pp.481~484 (2013)
73. Kamao H, "Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application", Stem Cell Reports, 2, pp.205~218 (2014)
74. Zimmermann A, "Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations", Stem Cells Dev, 21, pp.2364~2373 (2012)
75. Taylor CJ, "Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types", Cell Stem Cell, 11, pp.147~152 (2012)
76. Lin G, "HLA-matching potential of an established human embryonic stem cell bank in China", Cell Stem Cell, 5, pp.461~465 (2009)
77. Taylor CJ, "Immunological considerations for embryonic and induced pluripotent stem cell banking", Philos Trans R Soc Lond B Biol Sci, 366, pp.2312~2322 (2011)

관련 논문AI추천